CMB International Securities | Equity Research | Company Update

# GCL Technology (3800 HK)

# NDR takeaways: On-track capacity growth & cost reduction

We hosted a NDR for GCL last week. Key takeaways: (1) The construction of major production bases for FBR-based granular silicon have been on good tracks: (2) Unit cost of polysilicon will continue to decline with higher contribution of granular of which the unit consumption of electricity is much lower; (3) GCL's stake in GNE (451 HK) will reduce from 44.44% to 7.44% following the distribution of GNE shares to shareholders in specie, which will reduce GCL's financial burden and better facilitate the potential A-share listing. We expect all these will help GCL withstand the impact of a potential decline in polysilicon price in 2023E.

# Capacity and production:

- Xuzhou production base (100% interest): The new granular capacity of 30kt commenced in Jun and is expected to reach full utilization in 3Q. The current capacity of granular is 60kt and GCL targets to achieve production volume of 45kt in 2022E. GCL plans to upgrade the existing rod silicon capacity (45kt) to granular (40kt) in 2023E. After the upgrade, the total granular capacity in Xuzhou will reach 100kt.
- Leshan base (57.76%): Granular capacity of 100kt commenced operation in late Jul. GCL targets to achieve 30kt of production in 2022E.
- Baotou base (57.54%): Planned capacity of 100kt (phase 1) is under construction. After completing the stream recycling system, the capacity will start operation in late Oct. Production volume is expected to be ~5kt in 2022E. GCL expects full capacity utilization in 1H23E.
- Hohhot project (60%): The planned capacity is 100kt and the project construction started in late Aug and is expected to complete in 4Q23E. GCL believes that the progress could be faster than previous projects given the rich experience and the availability of manpower.
- Capacity and output target in 2022E. By end-2022E, the consolidated / attributable granular capacity is expected to reach 260kt / 175kt. Consolidated / attributable granular production in 2022E is expected to reach 75kt / 60kt, while the consolidated / attributable output of rod silicon is expected to be 105kt / 76kt.

# Cost and margin:

- Unit cost and margin in 1H22. GCL achieved unit gross margin of ~RMB155/kg of granular silicon, higher than rod silicon of RMB109/kg in 1H22. We estimate the unit cost of granular in 1H22 was close to ~RMB44/kg. For granular silicon, GCL reduced the comprehensive electricity consumption to 13.6 in 1H22, down from 14.8 in 2021. Such level is much lower than the 55-60 required by rod silicon.
- Further cost reduction on higher contribution of granular capacity located in lower power cost regions. In Leshan, tariff is RMB0.3/kWh, much lower than the ~RMB0.65/kWh in Xuzhou. In Baotou, tariff is even lower at RMB0.26/kWh. GCL believes that even if the tariff in Inner Mongolia increases to RMB0.45/kWh, GCL is still able to maintain the cost advantage as the cost structure of granular silicon is less sensitive to electricity cost.



# **NOT RATED**

**Current Price** 

HK\$2.76

# **China Solar Power**

Wayne Fung, CFA (852) 3900 0826 waynefung@cmbi.com.hk

Sto	ck	Data
	-	(1. I. A. A. A.

Mkt Cap (HK\$ mn)	74,819
Avg 3 mths t/o (HK\$ mn)	838
52w High/Low (HK\$)	3.99/1.98
Total Issued Shares (mn)	27,109
Source: Bloomberg	

23.5%
76.5%

Source: HKEx

## Share Performance

	Absolute	Relative
1-mth	-11.5%	-10.1%
3-mth	-1.8%	6.5%
6-mth	-7.1%	7.3%
Source: Bloomberg	r	

## **12-mth Price Performance**



Source: Bloomberg

#### Auditor: Crowe



# Perovskite technology:

GCL has established 100MW of solar cells with perovskite technology. Currently, the conversion efficiency (module) is on track to improve from 14% to 16%, and is expected to reach 18% in 2023E. However, it is still far below that of PERC, TOPCon and HJT. At laboratory stage, the conversion efficiency is yet to exceed 26% (vs a max 31.3% in theory). At present, GCL has yet to decide which types of perovskite technologies for development, including the raw materials and the structure of cells. The Company believes that it will take years to see real impact in the market.



# **Disclosures & Disclaimers**

# **Analyst Certification**

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report.

Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

CMBIGM Ratings BUY HOLD SELL NOT RATED	: Stock with potential return of over 15% over next 12 months : Stock with potential return of +15% to -10% over next 12 months : Stock with potential loss of over 10% over next 12 months : Stock is not rated by CMBIGM
OUTPERFORM	: Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM	: Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM	: Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM. Additional information on recommended securities is available upon request.

#### For recipients of this document in the United Kingdom

This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time)("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.,) of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

#### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analysts is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

#### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.